Key result
Higher HbA1c is linked to ~30% greater risk of poor 3-month functional outcomes in ischemic stroke.
Why the study?
The relationship between high HbA1c levels and short- and long-term functional outcomes after ischemic stroke, and its variation by stroke subtype and age, was unclear.
Does high HbA1c increase the risk of poor functional outcomes in patients with ischemic stroke?
Cohort (n=7,380)
Yes
Does high HbA1c increase the risk of poor functional outcomes in patients with ischemic stroke?
Odds Ratio: 1.299 (95% CI 1.098–1.535)
Pre-stroke hyperglycemia, as reflected by HbA1c ≥6.5%, is a significant predictor of poor functional prognosis after ischemic stroke, particularly in young- and middle-aged adults with small vessel occlusion.
May refine post-stroke prognostication via HbA1c; leaves open whether intervention alters outcomes in younger patients.
Objectives: To determine whether high HbA1c levels are related to short-and long-term functional outcomes in patients with ischemic stroke (IS) and whether this association differs according to the IS subtype and the patient's age. Methods: The data of 7,380 IS patients admitted to 16 hospitals or regional stroke centers in South-Korea, between May 2017 and December 2019, were obtained from the Clinical Research Collaboration for Stroke-Korea-National Institute of Health database and retrospectively analyzed. Among these patients, 4,598 were followed-up for one-year. The HbA1c levels were classified into three groups (<5.7, 5.7 to <6.5%, ≥6.5%). Short-and long-term poor functional outcomes were defined using the modified Rankin Scale score of 2 to 6 at three-months and one-year, respectively. IS subtypes were categorized according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification. Results: There was an association between higher HbA1c (≥6.5%) and poor functional outcomes at three-months in all patients (three-months; OR, 1.299, 95% CI 1.098, 1.535, one-year; OR, 1.181, 95% CI 0.952, 1.465). When grouped by age, the associations after both 3 months and 1 year observed in younger adult group (<65 years), but not in group aged 65 years and older (three-months; <65 years OR, 1.467, 95% CI 1.112, 1.936, ≥65 years OR, 1.220, 95% CI 0.987, 1.507, p for interaction = 0.038, one-year; <65 years OR, 1.622, 95% CI 1.101, 2.388, ≥65 years OR, 1.010, 95% CI 0.778, 1.312, p for interaction = 0.018). Among younger adult group, the higher HbA1c level was related to short-and long-term functional loss in patients with the small vessel occlusion subtype (three-months; OR, 2.337, 95%CI 1.334, 4.095, one-year; OR, 3.004, 95% CI 1.301, 6.938). However, in patients with other TOAST subtypes, a high HbA1c level did not increase the risk of poor outcomes, regardless of the age of onset. Conclusion: High HbA1c levels increase the risk of short-and long-term poor functional outcomes after IS onset. However, this association differs according to stroke subtype and age. Thus, pre-stroke hyperglycemia, reflected by HbA1c, may be a significant predictor for a poor prognosis after ischemic stroke, particular in young- and middle-aged adults.
No takes yet. Share an insight, caveat, or question.
Park et al. (2023) conducted a cohort in Ischemic stroke (n=7,380). High HbA1c levels (≥6.5%) vs. HbA1c <6.5% was evaluated on Poor functional outcomes (modified Rankin Scale score of 2 to 6) at three-months (OR 1.299, 95% CI 1.098-1.535). Higher HbA1c levels (≥6.5%) were associated with poor functional outcomes at 3 months in ischemic stroke patients (OR 1.299; 95% CI 1.098-1.535), particularly in younger adults (<65 years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: